Molecular response to imatinib mesylate following relapse after allogeneic SCT for CML [1]

Blood

Volumn 101, Issue 3, 2003, Pages 1200-1201

  McCann, Shaun R ^a  

^a ST JAMES S HOSPITAL   (Ireland)

Author keywords

[No Author keywords available]

Indexed keywords

BCR ABL PROTEIN; IMATINIB;

CASE REPORT; CHIMERA; CHRONIC MYELOID LEUKEMIA; CLINICAL FEATURE; CLONE; CYTOGENETICS; DISEASE COURSE; GENETIC TRANSCRIPTION; HUMAN; LETTER; MALE; MOLECULAR GENETICS; POLYMERASE CHAIN REACTION; PRIORITY JOURNAL; RELAPSE; STEM CELL TRANSPLANTATION; TREATMENT OUTCOME;

EID: 0037309057     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood-2002-09-2932     Document Type: Letter

References (8)

1. Kantarjian HM, O'Brien S, Cortes JE, et al. Imatinib mesylate therapy for relapse after allogeneic stem cell transplantation for chronic myelogenous leukemia. Blood. 2002;100:1590-1595.
2. Gratwohl A, Hermans J, Niederwieser D, et al. Bone marrow transplantation for chronic myeloid leukemia.: long-term results. Bone Marrow Transplant. 1993;12:509-516.
3. Cross NCP, Feng L, Chase A, et al. Competitive polymerase chain reaction to estimate the number of BCR/ABL transcripts in chronic myeloid leukemia patients after bone marrow transplantation. Blood. 1993;82:1929-1936.
4. Arcese W, Goldman J, D'Arcangelo E, et al. Outcome for patients who relapse after allogeneic bone marrow transplantation for chronic myeloid leukemia. Blood. 1993;82:3211-3219.
5. Dazzi F, Szydlo RM, Craddock C, et al. Durability of response following donor lymphocyte infusions for patients who relapse after allogeneic stem cell transplantation for chronic myeloid leukemia. Blood. 2000;95:67-71.
6. Keil F, Haas OA, Fritsch G, et al. Donor leukocyte infusion for leukemic relapse after allogeneic marrow transplantation: lack of residual donor hematopoiesis predicts aplasia. Blood 1997;89:3113-3117.
7. Lawler M, Humphries P, McCann SR. Evaluation of mixed chimerism by in vitro amplification of dinucleotide repeat sequences using the polymerase chain reaction. Blood 1991;77:2504-2514.
8. O'Dwyer ME, Mauro MJ, Kurilik G, et al. The impact of clonal evolution on response to imatinib mesylate (STI571) in accelerated phase CML. Blood 2002;100:1628-1633.